{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T18:20:05Z","timestamp":1765650005335,"version":"3.48.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,13]]},"DOI":"10.7759\/cureus.99140","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T18:16:23Z","timestamp":1765649783000},"source":"Crossref","is-referenced-by-count":0,"title":["Low-Grade B-cell Lymphoma in Primary Sj\u00f6gren\u2019s Syndrome: A Case Report"],"prefix":"10.7759","author":[{"given":"Thanda","family":"Aung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Botten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anamaria","family":"Munteanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bita V","family":"Naini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Pastizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanwarpal S","family":"Kahlon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sj\u00f6gren's syndrome","volume":"378","author":"Mariette X","year":"2018","unstructured":"Mariette X, Criswell LA. Primary Sj\u00f6gren's syndrome. N Engl J Med. 2018, 378:931-9. 10.1056\/NEJMcp1702514","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04522-7","article-title":"Prevalence and clinical presentation of lymphoproliferative disorder in patients with primary Sj\u00f6gren's syndrome","volume":"40","author":"Sebastian A","year":"2020","unstructured":"Sebastian A, Madej M, Sebastian M, Butrym A, Woytala P, Ha\u0142o\u0144 A, Wiland P. Prevalence and clinical presentation of lymphoproliferative disorder in patients with primary Sj\u00f6gren's syndrome. Rheumatol Int. 2020, 40:399-404. 10.1007\/s00296-020-04522-7","journal-title":"Rheumatol Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200402","article-title":"Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjogren's syndrome in Taiwan","volume":"71","author":"Weng MY","year":"2012","unstructured":"Weng MY, Huang YT, Liu MF, Lu TH. Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjogren's syndrome in Taiwan. Ann Rheum Dis. 2012, 71:524-7. 10.1136\/annrheumdis-2011-200402","journal-title":"Ann Rheum Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13192","article-title":"Sj\u00f6gren Syndrome-associated lymphomas: an update on pathogenesis and management","volume":"168","author":"Nocturne G","year":"2015","unstructured":"Nocturne G, Mariette X. Sj\u00f6gren Syndrome-associated lymphomas: an update on pathogenesis and management. Br J Haematol. 2015, 168:317-27. 10.1111\/bjh.13192","journal-title":"Br J Haematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3181b76ab5","article-title":"Hematologic manifestations and predictors of lymphoma development in primary Sj\u00f6gren syndrome: clinical and pathophysiologic aspects","volume":"88","author":"Baimpa E","year":"2009","unstructured":"Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM. Hematologic manifestations and predictors of lymphoma development in primary Sj\u00f6gren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore). 2009, 88:284-93. 10.1097\/MD.0b013e3181b76ab5","journal-title":"Medicine (Baltimore)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/art.39518","article-title":"Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sj\u00f6gren\u2019s syndrome","volume":"68","author":"Nocturne G","year":"2016","unstructured":"Nocturne G, Virone A, Ng WF, et al.. Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sj\u00f6gren\u2019s syndrome. Arthritis Rheumatol. 2016, 68:977-85. 10.1002\/art.39518","journal-title":"Arthritis Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103084","article-title":"Primary Sj\u00f6gren's syndrome is associated with increased risk of malignancies besides lymphoma: a systematic review and meta-analysis","volume":"21","author":"Zhong H","year":"2022","unstructured":"Zhong H, Liu S, Wang Y, Xu D, Li M, Zhao Y, Zeng X. Primary Sj\u00f6gren's syndrome is associated with increased risk of malignancies besides lymphoma: a systematic review and meta-analysis. Autoimmun Rev. 2022, 21:103084. 10.1016\/j.autrev.2022.103084","journal-title":"Autoimmun Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003766","article-title":"Predicting the risk for lymphoma development in Sjogren syndrome: an easy tool for clinical use","volume":"95","author":"Fragkioudaki S","year":"2016","unstructured":"Fragkioudaki S, Mavragani CP, Moutsopoulos HM. Predicting the risk for lymphoma development in Sjogren syndrome: an easy tool for clinical use. Medicine (Baltimore). 2016, 95:e3766. 10.1097\/MD.0000000000003766","journal-title":"Medicine (Baltimore)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-005-1084-y","article-title":"Idiopathic portal hypertension associated with systemic sclerosis and Sj\u00f6gren's syndrome","volume":"24","author":"Kogawa H","year":"2005","unstructured":"Kogawa H, Migita K, Ito M, et al.. Idiopathic portal hypertension associated with systemic sclerosis and Sj\u00f6gren's syndrome. Clin Rheumatol. 2005, 24:544-7. 10.1007\/s10067-005-1084-y","journal-title":"Clin Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000037158","article-title":"Splenic marginal zone lymphoma with monoclonal IgG: a case report","volume":"103","author":"Zhang X","year":"2024","unstructured":"Zhang X, Ren S, Zhang N, et al.. Splenic marginal zone lymphoma with monoclonal IgG: a case report. Medicine (Baltimore). 2024, 103:e37158. 10.1097\/MD.0000000000037158","journal-title":"Medicine (Baltimore)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2147\/IMCRJ.S539313","article-title":"Splenectomy for primary Sj\u00f6gren\u2019s syndrome associated with massive splenomegaly: two case reports","volume":"18","author":"Gui F","year":"2025","unstructured":"Gui F, Zhou LX, Liu XM, He YL, Yang QB. Splenectomy for primary Sj\u00f6gren\u2019s syndrome associated with massive splenomegaly: two case reports. Int Med Case Rep J. 2025, 18:963-8. 10.2147\/IMCRJ.S539313","journal-title":"Int Med Case Rep J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab939","article-title":"Clinical picture, outcome and predictive factors of lymphoma in primary Sj\u00f6gren's syndrome: results from a harmonized dataset (1981-2021)","volume":"61","author":"Chatzis LG","year":"2022","unstructured":"Chatzis LG, Stergiou IE, Goules AV, et al.. Clinical picture, outcome and predictive factors of lymphoma in primary Sj\u00f6gren's syndrome: results from a harmonized dataset (1981-2021). Rheumatology (Oxford). 2022, 61:3576-85. 10.1093\/rheumatology\/keab939","journal-title":"Rheumatology (Oxford)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/art.40093","article-title":"Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjogren\u2019s syndrome","volume":"69","author":"Bowman SJ","year":"2017","unstructured":"Bowman SJ, Everett CC, O'Dwyer JL, et al.. Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjogren\u2019s syndrome. Arthritis Rheumatol. 2017, 69:1440-50. 10.1002\/art.40093","journal-title":"Arthritis Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110077","article-title":"Treatment of mucosa-associated lymphoid tissue lymphoma in Sjogren's syndrome: a retrospective clinical study","volume":"38","author":"Pollard RP","year":"2011","unstructured":"Pollard RP, Pijpe J, Bootsma H, et al.. Treatment of mucosa-associated lymphoid tissue lymphoma in Sjogren's syndrome: a retrospective clinical study. J Rheumatol. 2011, 38:2198-208. 10.3899\/jrheum.110077","journal-title":"J Rheumatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1561214","article-title":"Meta-analysis of the efficacy and safety of rituximab in the treatment of primary Sj\u00f6gren's syndrome","volume":"16","author":"Zheng X","year":"2025","unstructured":"Zheng X, Di J, Chen X, et al.. Meta-analysis of the efficacy and safety of rituximab in the treatment of primary Sj\u00f6gren's syndrome. Front Immunol. 2025, 16:1561214. 10.3389\/fimmu.2025.1561214","journal-title":"Front Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/440966-low-grade-b-cell-lymphoma-in-primary-sjgrens-syndrome-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T18:16:23Z","timestamp":1765649783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/440966-low-grade-b-cell-lymphoma-in-primary-sjgrens-syndrome-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.99140","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,13]]}}}